drug · antibody
patient view →elranatamab
Marketedupdated 2mo agoby $PFE PFIZER INC🔗 ChEMBL
Approvedcommunity read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for multiple myeloma and neoplasm and 2 investigational indications.
targets
T cell surface glycoprotein CD3Tumor necrosis factor receptor superfamily member 17
all catalysts(8)
approval · 7
phase 3 completion · 1
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that